What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?

Détails

ID Serval
serval:BIB_1E02677E0FC7
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?
Périodique
Current radiopharmaceuticals
Auteur(s)
Slavikova K., Montravers F., Treglia G., Kunikowska J., Kaliska L., Vereb M., Talbot J.N., Balogova S.
ISSN
1874-4729 (Electronic)
ISSN-L
1874-4710
Statut éditorial
Publié
Date de publication
06/06/2013
Peer-reviewed
Oui
Volume
6
Numéro
2
Pages
96-105
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Among thyroid malignancies, medullary thyroid carcinoma (MTC) has some very specific features. Production and secretion of large amounts of peptides occur in malignant transformed C cells with few exceptions, leading to high serum levels of calcitonin (Ctn) and carcinoembryonic antigen (CEA), that act after thyroidectomy as tumour markers warning for the presence of persistent or metastatic MTC. The availability of those serum biomarkers with an excellent sensitivity challenges medical imaging to localise the recurrent cancer tissue, since surgery is a major therapeutic option. The aims of this article are (i) to review literature evidence about the efficacy and tolerance of radiopharmaceuticals for 3 targets of PET/CT imaging (glucose metabolism, bioamines metabolism and somatostatin receptors) and also bone scintigraphy which is recommended in the Guidelines of European Society for Medical Oncology (ESMO; (ii) to compare the availability and the costs in relation with those radiopharmaceuticals, (iii) and to discuss a possible sequence of those examinations, in order to optimise spending and to minimise the overall radiation dose. In this context of recurrent MTC suspected on rising tumour markers levels after thyroidectomy, this survey of literature confirms that FDOPA is the best radiopharmaceutical for PET/CT with significant diagnostic performance if Ctn>150 pg/mL; an early image acquisition starting during the first 15 min is advised. In negative cases, FDG should be the next PET radiopharmaceutical, in particular if Ctn and CEA levels are rapidly rising, and PET with a somatostatin analogue labelled with gallium-68 when neither FDOPA nor FDG PET are conclusive. Bone scintigraphy could complement FDG-PET/CT if FDOPA is not available.

Mots-clé
Amines/metabolism, Blood Glucose/metabolism, Bone and Bones/diagnostic imaging, Carcinoma, Neuroendocrine, Dihydroxyphenylalanine/analogs & derivatives, Fluorine Radioisotopes, Fluorodeoxyglucose F18, Humans, Multimodal Imaging/economics, Multimodal Imaging/methods, Neoplasm Recurrence, Local/diagnostic imaging, Neoplasm Recurrence, Local/economics, Positron-Emission Tomography/economics, Positron-Emission Tomography/methods, Radiation Dosage, Radiopharmaceuticals/economics, Receptors, Somatostatin/metabolism, Thyroid Neoplasms/diagnostic imaging, Thyroid Neoplasms/economics, Tomography, X-Ray Computed/economics, Tomography, X-Ray Computed/methods
Pubmed
Création de la notice
20/08/2017 20:33
Dernière modification de la notice
03/03/2018 14:35
Données d'usage